Načítá se...
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children
BACKGROUND: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s lymphoma are limited. METHODS: We conducted an open-label, international, randomized, phase 3 trial involving patien...
Uloženo v:
| Vydáno v: | N Engl J Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7720281/ https://ncbi.nlm.nih.gov/pubmed/32492302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1915315 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|